Research programme: tri-specific natural killer-cell engagers - Merck
Latest Information Update: 25 Apr 2022
At a glance
- Originator Merck AG
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 11 Apr 2022 Merck and Artiva Biotherapeutics extends the agreement to evaluate Merck's tri-specific NK-cell engager candidates with AB 101
- 11 Apr 2022 Early research in Cancer in Germany (Parenteral)
- 28 Jan 2021 Artiva Biotherapeutics and Merck enters into a worldwide collaboration and license agreement